Kornimate/medical-research-clean huggingface dataset:
clopidogrel response evaluation and anti-platelet intervention in high thrombotic risk pci patients

Conditions: Coronary Heart Disease

Summary: to identify the high-risk patients who might have in-stent thrombosis after pci with thromboelastography and to head-to-head compare two intensified antiplatelet therapeutic strategies of double-dosage clopidogrel and triple antiplatelet therapy with cilostazol with the standard antiplatelet therapy.

study population: age 18 - 75, male or non-pregnant female; stable or unstable angina with evidence of myocardial ischemia, or patient with myocardial infarction; coronary angiography reveals stenosis lesions; discovery of adp induced platelet inhibition rate \ 47mm via thromboelastography (indicating low responsiveness to clopidogrel with high risk for stent thrombosis formation); is able to understand the objective of the trial, takes part voluntarily and signs the written informed consent form.

Eligibility criteria:
inclusion criteria: 1. age 18 - 75, male or non-pregnant female; 2. stable or unstable angina with evidence of myocardial ischemia, or patient with myocardial infarction; 3. coronary angiography reveals stenosis lesions; 4. discovery of adp induced platelet inhibition rate \ 47mm via thromboelastography (indicating low responsiveness to clopidogrel with high risk for stent thrombosis formation); 5. is able to understand the objective of the trial, takes part voluntarily and signs the written informed consent form. exclusion criteria: 1. those who have participated in other drug or therapy equipment clinical trials but did not reach the main study endpoint time limit; 2. symptoms of severe heart failure (nyha class iii and above) or left ventricular ejection fraction \< 40% (ultrasound or left ventricle ngiography); 3. pregnant or lactating women; 4. severely impaired renal function before surgery: serum creatinine \> 2.0mg/dl; 5. impaired liver function before surgery: serum gpt \> 120u/l; 6. bleeding tendency, history of active peptic ulcer, history of cerebral hemorrhage or cavum subarachnoidale bleeding, patients with antiplatelet agent and anticoagulant treatment contraindications and hence are unable to undergo anticoagulant therapy; 7. patients who are unable to withstand dual antiplatelet therapy due to allergy to aspirin, clopidogrel or ticlopidine, heparin, contrast agent, paclitaxel and metals; 8. leucocyte \ 750,000/mm3; 9. patient's life expectancy is less than 12 months; 10. patients who plan to undergo coronary artery bypass grafting or other surgery within 1 year; 11. those waiting for heart transplant; 12. patients who are deemed by the researchers to have low compliance and unable to abide by the requirements and complete the study.

Keywords: pci platelet function monitoring thrombelastography clopidogrel cilostazol in-stent thrombosis
safety trial of opc-61815 injection in patients with congestive heart failure who have difficulty with or are incapable of oral intake

Conditions: Congestive Heart Failure

Summary: to confirm the tolerability of intravenous administration of opc-61815 at 8 or 16 mg once daily for a maximum of 5 days to chf patients with volume overload despite having received diuretics (injection) other than vasopressin antagonists and who have difficulty with or are incapable of oral intake.


Eligibility criteria:
inclusion criteria: * patients receiving loop diuretic injection at a dose equivalent to furosemide 20 mg/day or higher * chf patients in whom lower limb edema, pulmonary congestion, and/or jugular venous distension due to volume overload is present * patients who are judged by the investigator or subinvestigator to have difficulty or be incapable of oral intake, including patients who are judged by the investigator or subinvestigator to require nothing by mouth(npo) management * patients who are currently hospitalized or who are capable of being hospitalized from the time of informed consent until the end of the treatment period * patients who are capable of giving informed consent exclusion criteria: * patients who are on a ventricular assist device * patients who have difficulty with spontaneous respiration or who have been on tracheal intubation under sedative therapy * patients with severe disturbed consciousness (ie, coma or stupor)
impact of conservative treatment by custom-made orthoses in patients with haemophilic ankle arthropathy

Conditions: Haemophilia A; Haemophilia B

Summary: the purpose of this study intend to evaluate the effectiveness of functional orthoses (including custom-made insoles and shoes) for preventing and controlling repetitive haemarthrosis in patients suffering of haemophilic ankle arthropathy, as well as the orthoses' impact on foot health-related quality of life.


Eligibility criteria:
inclusion criteria: * haemophilia a or b, aged more than 13 years exclusion criteria: * impossibility to walk on a treadmill * recent joint haemarthrosis or muscle haematoma

Keywords: patients with haemophilia a moderate or severe patients with haemophilia b moderate or severe
nebivolol anoca treatment randomized trial

Conditions: ANOCA - Angina With Non-obstructive Coronary Arteries; Coronary Microvascular Dysfunction (CMD)

Summary: to determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction.

objective to determine the effectiveness of the beta-blocker nebivolol in controlling symptoms and improving the quality of life in patients with angina and coronary microvascular dysfunction. hypothesis treatment with titrated nebivolol will result superior to placebo in symptoms control in patients presenting with coronary microvascular disease (cmd). study design prospective, multicenter, controlled, double-blinded, randomized clinical trial. inclusion criteria • patients over 18 years old with symptoms or evidence of myocardial ischemia and coronary arteries without lesions or with epicardial lesions (\ 0.80 / rfr \>0.90), and • cfr ≤ 2.0 and/or imr≥25 exclusion criteria life expectancy \<1 year, inability to provide informed consent, severe valve disease, left ventricular ejection fraction \<30%, clinical contraindication for betablockers treatment. treatment arms randomization will be performed after invasive diagnostic of cmd: study group: nebivolol • patients will start with a dose of 5 mg every 24 hours. biweekly dose adjustments will be performed during the first two months, increasing the dose (if tolerated with respect to heart rate, blood pressure, and symptoms) up to a maximum of 20 mg/24 hours. control group: placebo • patients will be treated with one tablet every 24 hours. primary endpoint: the effectiveness of nebivolol treatment in improving angina symptoms was measured using the saq questionnaire after 6 months of treatment. secondary endpoints • quality of life at 6 months. * functional capacity at 6 months. * major cardiac events at 1 year.

Eligibility criteria:
inclusion criteria: * age 18 years or older. * presence of stable angina symptoms, defined as compatible symptoms occurring at least once weekly in the last three months. * absence of functionally significant epicardial coronary artery disease (ffr \> 0.80). * microvascular functional study showing cfr\< 2,0 and/or imr ≥ 25. exclusion criteria: * allergy or contraindication to the use of beta-blockers. * indication for beta-blocker treatment due to another pathology. * ventricular dysfunction (lvef \< 45%). * percutaneous coronary revascularization in the last 6 months. * history of surgical revascularization. * first-degree atrioventricular block or bifascicular block. * presence of hemodynamically significant valvulopathy. * presence of cardiomyopathy or congenital cardiac anomaly. * severe renal insufficiency (egfr \< 30 ml/min). * liver failure (history of cirrhosis or transaminase elevation \> 3 times the upper limit of normal). * pregnant or lactating women.

Keywords: coronary microvascular disease betablockers angina
construction and application of a risk prediction model forepistaxis after pituitary tumor resection

Conditions: Pituitary Tumor

Summary: (1) objective to establish an evaluation system for predicting the risk of epistaxis after endoscopic transsphenoidal pituitary surgery（ 2) objective to determine the risk factors of epistaxis after endoscopic transsphenoidal pituitary adenoma surgery. referring to domestic and foreign literature, combined with experts' opinions, the related risk factors that may cause postoperative nosebleed of pituitary adenoma are: 22 patients and surgical factors. 3) objective to establish a risk prediction model of epistaxis after endoscopic transsphenoidal pituitary tumor resection. according to the occurrence of epistaxis, the patients in the modeling group were divided into epistaxis group and non epistaxis group. the risk factors of epistaxis were taken as the independent variable, and the occurrence of epistaxis was taken as the dependent variable. the variables with statistical significance in univariate analysis were included in the multivariate logistic regression model, and the risk prediction model of epistaxis after pituitary tumor resection was established by back lr method.(4) objective to verify the risk prediction model of endoscopic transsphenoidal pituitary adenoma epistaxis. the validation model is used to validate the prediction model, and the hosmer-lemeshow degree is used to match the model. the area under the receiver operating characteristic curve (roc) was used to evaluate the validity of the model.(5) application of risk prediction model.


Eligibility criteria:
inclusion criteria: those who met the diagnostic criteria of pituitary tumor and received transsphenoidal endoscopic surgery during hospitalization; patients with informed consent; age ≥ 14 years old. exclusion criteria: quitters; patients with incomplete clinical data;
a study in south korea using medical records to look at different treatments for chronic obstructive airway disease (copd)

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: non-interventional, single-country study based on existing data from medical records of copd patients treated with lama or fixed dose combination of ics/laba


Eligibility criteria:
inclusion criteria: * diagnosed with copd \[based on icd-10 code(j43.x-44.x except j430), as the primary or within the fourth secondary diagnosis and initiated lama or ics/laba more than twice a year from jan 1, 2005 to apr 30 2016\]. * age \>55 years old exclusion criteria: * prescription history with any long acting bronchodilator for maintenance therapy (the patient should be inhaler naïve) * prescription history with ipratropium bromide * prescription history with leukotriene receptor antagonist(ltra) or ics * patients with lung cancer, ipf, ild or lung transplantation at the time of copd diagnosis
adjunctive photodynamic therapy in treatment of chronic periodontitis

Conditions: Chronic Periodontitis

Summary: the aim of this study is to verify the efficacy of photodynamic therapy (pdt) as an adjunct to non-surgical treatment of chronic periodontitis by assessing clinical and microbiological and immunological parameters. this is a randomized, controlled, double-blind, parallel clinical trial. thirty eight patients with chronic periodontitis will receive conventional periodontal treatment. after eight weeks, patients will be re-evaluated and sites with residual pockets (pd ≥ 5 mm ) will be selected as experimental sites, and will be allocated to test and control group randomly. the test group will receive the application of pdt and the control group will receive sham procedure. the clinical parameters will be evaluated at baseline, 3, 6 and 12 months after treatment. subgingival plaque will be collected before pdt, a week after, 3, 6 and 12 months later. the microbiological evaluation will detect and quantify periodontal pathogens such as porphyromonas gingivalis, tannerella forsythia, treponema denticola and aggregatibacter actinomycetencomitans with real time-pcr. during follow-up, patients will receive periodontal maintenance every 3 months, as well as the application of pdt or sham

the goal of periodontal treatment is to restore tissue health through the elimination and control of etiologic factors, reducing the microbial aggression. some microorganisms persist in the root surface even after scraping. thus, the conventional mechanical treatment may fail to reduce the number of periodontal pathogens to levels compatible with health. this study will verify the efficacy of photodynamic therapy (pdt) as an adjunct to non-surgical treatment of chronic periodontitis.

Eligibility criteria:
inclusion criteria: * chronic periodontitis (tonetti, claffey, 2005) * 10 or more teeth * 2 or more site with probing pocket depth ≥ 5 mm, with or without bleeding on probing, after re-evaluation exclusion criteria: * profilatic antibiotics * diabetes, immunosuppression, pregnancy nursing mother * smoking * medication that might interfere with periodontal healing * previous periodontal treatment or antibiotics (6 months) * experimental teeth with mobility ii or iii, or endodontic problem

Keywords: periodontitis photodynamic therapy
feasibility of auricular acupressure as an adjunct treatment for neonatal abstinence syndrome (nas)

Conditions: Neonatal Abstinence Syndrome; Withdrawal

Summary: this study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (nas) at monroe carrell jr children's hospital at vanderbilt university medical center (vumc).

nas is a condition in which newborns experience withdrawal symptoms as a result of in utero exposure to opioids and/or other substances ingested by the mother. the condition has significantly risen over the past 20 years. first line treatments for nas involve the maximization of non-pharmacologic therapies. nas management focuses on reducing or eliminating the need for medication management to prevent further developmental complications, promote maternal bonding, and reduce hospital length of stay. auricular acupuncture has been used for the treatment of addiction and has demonstrated efficacy in the adult population. current evidence suggests that acupuncture is safe and beneficial for multiple conditions that impact neonatal and pediatric populations including nas. acupressure is a less invasive therapy and may serve as an additional non-pharmacological adjunct to ease the severe discomfort of withdrawal in neonates at risk for nas. this study will assess the feasibility of implementing auricular acupressure as an additional non-pharmacologic therapy for neonates at risk for developing neonatal abstinence syndrome (nas) at monroe carrell jr children's hospital at vanderbilt university medical center (vumc).

Eligibility criteria:
inclusion criteria: * 37 weeks gestational age or greater * maternal age 16 or older * substance exposure in utero including opioids, illicit drugs, or other medications that cause neonatal withdrawal exclusion criteria: * birth trauma * neonatal asphyxia * maternal or neonatal infection * congenital abnormalities * requiring neonatal intensive care unit (nicu) care

Keywords: acupressure
the efficacy of botulinum toxin in overactive bladder

Conditions: Overactive Bladder

Summary: to assess the efficacy of botulinum toxin injection in overactive bladder.

detrusor overactivity is defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase that may be spontaneous or provoked. detrusor overactivity is subdivided into idiopathic detrusor overactivity and neurogenic detrusor overactivity the international continence society (ics) defines oab as the presence of "urinary urgency, usually accompanied by frequency and nocturia, with or without urgency urinary incontinence, in the absence of uti or other obvious pathology. neurogenic detrusor overactivity (ndo) can result in lower and upper urinary tract complications and eventually even in end-stage kidney failure. since the driving force of this clinical cascade is high bladder pressure, controlling intravesical pressure in ndo patients improves both quality of life and life-expectancy in these patients. botulinum toxin a (btx-a) has proven its efficacy in reducing intravesical pressure and in reducing incontinence episodes. btx-a also improves quality of life in patients with ndo. both onabotulinumtoxina (botox®, allergan, irvine, usa) and abobotulinumtoxina (dysport®, ipsen, paris, france) have a level a recommendation for ndo-treatment. the recommended dose for intradetrusor injections in ndo patients is 200 u of onabotulinumtoxina or 500 u of abobotulinumtoxina. the drug is generally administered extratrigonal in the detrusor muscle, via cystoscopic guided injection at 20 sites in 1 ml injections. intradetrusor btx-a injections are safe, with mostly local complications such as urinary tract infection and high post-void residual or retention. the effect of the toxin lasts for approximately 9 months. repeat injections can be performed without loss of efficacy. different injection techniques, novel ways of btx-a administration, eliminating the need for injection or new btx-a types with better/longer response rates could change the field in the future. botulinum toxins are neurotoxins produced by the facultative anaerobe clostridium botulinum that block the release of acetylcholine into the synaptic gap of the neuromuscular junction. their injection near the nerves that supply the target organ selectively and temporarily paralyzes the organ. in particular, the subtype botulinum-a toxin is widely used in neurology to release spastic dystonia in adults. and children. in urologic disorders, botulinum-a toxin reliably diminishes external sphincter or detrusor overactivity.

Eligibility criteria:
1. inclusion criteria: * patients with spastic neurogenic bladder due to upper motor neuron lesion as (spinal cord lesions ,multiple sclerosis ,strokes,parkinsonism...........). * patients with idiopathic overactive bladder * patients with spastic neurogenic bladder diagnosed clinically and urodynamically. 2. exclusion criteria: * patients with diabetes mellitus. * atonic bladder. * children below 6 years.
mesenteric panniculitis : review of consecutive abdominal mdct examinations with a matched-pair analysis

Conditions: Mesenteric Panniculitis

Summary: mesenteric panniculitis is a benign inflammatory condition that involves the adipose tissue of the intestinal mesentery. clinical manifestations are uncommon, non specific and atypical. mesenteric panniculitis is thus most often an incidental finding during an investigation for other reason, mostly on computed tomography scans. the rate of malignancy in patients with mesenteric panniculitis, especially urogenital and gastrointestinal adenocarcinomas or lymphomas, has been reported to be as high, thus suggesting that there may be a relationship between mesenteric panniculitis and progression of an underlying malignancy or the risk of a future malignancy.

the aim was: to estimate the prevalence of mesenteric panniculitis. to study relationship between mesenteric panniculitis and malignancy. to investigate the 5-year outcome of patients with mesenteric panniculitis for the development of malignancy.

Eligibility criteria:
inclusion criteria: * patients with a ct scan from january to august 2008 * patients with diagnosis of mesenteric panniculitis on ct scan exclusion criteria: * patients with disease that may cause mesenteric infiltration
longitudinal study of intra-uterine growth restriction

Conditions: IUGR; Pregnancy

Summary: the investigation will employ a longitudinal approach in which every fetus diagnosed to be sga (small for gestational age ) will be studied at frequent intervals with sophisticated imaging techniques to assess subtle physiologic changes in the brain, heart, and placenta over time. these findings will be correlated with neurological and cardiovascular function in the newborn and early childhood. this research initiative should yield diagnostic and therapeutic templates that will improve the quality of life of iugr babies in addition to providing important information that will better inform current diagnostic practices.

the overarching objective is to serially assess changes in the fetal circulation, heart, and brain with sophisticated ultrasound, mri (magnetic resonance imaging), and body composition techniques that will provide clues as to how growth restricted babies will tolerate life outside the uterus. employing a longitudinal study will allow the investigators to correlate perinatal and postnatal outcomes more comprehensively than previous studies.

Eligibility criteria:
inclusion criteria: * patients with diagnosed sga by an ultrasound estimated fetal weight (efw) of less than the 10th percentile or a fetal abdominal circumference of less than the 5th percentile will be included in the study at the time of their first examination. exclusion criteria: * patients \< 18 years of age, and chromosomal anomalies as identified by regular aneuploidy screening.

Keywords: pregnancy iugr small for gestational age
stone access and removal (star) study

Conditions: Kidney Calculi

Summary: the purpose of the study is to assess procedural completion, the post-operative stone clearance and the safety profile following robotic mini-percutaneous nephrolithotomy (pcnl) performed with the monarch platform, urology.


Eligibility criteria:
inclusion criteria: * simple renal caliceal and/or pyelo stone(s) with stone burden =\> 1 cm, identified on ct scan, and appropriate for pcnl treatment according to aua guidelines * normal upper tract anatomy, amenable to pcnl and ureteroscopy * participants with a percutaneous tract length \< 15 cm as measured by the estimation of the skin to stone or skin to appropriate calyx for treatment through a ct scan * participant is an appropriate candidate for a mini-pcnl based on the clinical guidelines and investigator assessment. exclusion criteria: pre-procedure:exclusion criteria: * any medical or physical condition/limitation that would contra-indicate a conventional ureteroscopy or pcnl in the supine position (e.g., atypical interposition of visceral organs (bowel, spleen, or liver)) * expected additional procedure, or participation in any clinical trial, from 30 days prior to the study procedure and throughout the duration of the study, which might impact this study's results * a solitary functioning kidney * female participants who are pregnant or nursing or those of child-bearing potential refusing a pregnancy test * presence of ureteral impacted stones intra-procedure exclusion criteria: - any presenting condition discovered intra-procedurally that in the opinion of the investigator would make participating in this study not in the participant's best interest.

Keywords: nephrolithotomy percutaneous ureteroscopy robotic monarch kidney calculi